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Abstract. We describe a case of persistent strongyloidiasis complicated by recurrent meningitis, in a human T cell
lymphotropic virus type 1 (HTLV-1) seropositive Peruvian migrant adult resettled in Italy. He was admitted with signs and
symptoms of acute bacterial meningitis, reporting four other meningitis episodes in the past 6 years, with an etiological
diagnosis of Escherichia coli and Enterococcus faecium in two cases. He had been previously treated with several
antihelmintic regimens not including ivermectin, without eradication of strongyloidiasis, and he had never been tested for
HTLV before. During the described episode, the patient was treated for meningitis with broad-spectrum antibiotic therapy
and 200 mg/kg/dose oral ivermectin once daily on day 1, 2, 15 and 16 with full recovery and no further episodes of
meningitis. The presented case underlines several critical points concerning the management of poorly known neglected
diseases such as strongyloidiasis and HTLV infection in low-endemic areas. Despite several admissions for meningitis and
strongyloidiasis, the parasitic infection was not adequately treated and the patient was not previously tested for HTLV. The
supply of ivermectin and the choice of treatment scheme was challenging since ivermectin is not approved in Italy and there
are no standardized guidelines for the treatment of severe strongyloidiasis in HTLV seropositive subjects.
INTRODUCTION
Strongyloidiasis is a nematode infection caused by
Strongyloides stercoralis, widely distributed in tropical and
subtropical areas, with some foci of low endemicity even in
temperate areas.1 The infection is acquired primarily by walk-
ing bare foot on ground contaminated with infective larvae
that are eliminated with stools by parasitized subjects. Once
the subject has been infected, in the absence of appropriate
treatment, S. stercoralis is able to persist indefinitely in the
host through a so called autoinfective cycle. The infection is
frequently unrecognized because it can be completely asymp-
tomatic; or it may cause mild and nonspecific clinical complains
such as itching, gastrointestinal discomfort, respiratory symp-
toms; or it can be responsible of asymptomatic eosinophilia.1
Moreover the diagnosis is difficult because it requires a combi-
nation of dedicated techniques such as blood agar plate culture
of stool and specific serology since the direct parasitological
examination of stool is insensitive.2 Even more challenging is
the diagnosis in immunocompromised patients because sero-
logical tests may be negative.2
A peculiar characteristic of S. stercoralis is its ability to act
as an opportunistic agent in immunocompromised subjects in
whom it can cause hyperinfection syndrome and disseminated
strongyloidiasis, two conditions with a high fatality rate.3
Hyperinfection syndrome is characterized by the presence
of larvae confined to lungs and gastrointestinal tract, but with
signs/symptoms of severe diseases in relation to elevated
number of larvae, whereas disseminated strongyloidiasis is
defined in presence of larvae in any organ, other than the
respiratory and the gastrointestinal tracts.3
In such circumstances, the massive passage of intestinal
bacteria through the bowel wall can be responsible for severe
invasive bacterial diseases such as meningitis, which is the
most frequent central nervous system manifestation of dis-
seminated strongyloidiasis.4
Human T cell lymphotropic virus type 1 (HTLV-1) is a
retrovirus highly prevalent in some areas of Japan, Papua
New Guinea, South America, and West Africa.5 It is transmit-
ted through mother-to-child route (mainly through breast-
feeding), through blood transfusions, and through sexual route
causing a chronic infection. Only about 10% HTLV-1-infected
subjects develop a disorder related to the virus during their
life, including adult T-cell leukemia/lymphoma, HTLV-1-
associated myelopathy, uveitis, and opportunistic infections
(including strongyloidiasis). As a matter of fact, HTLV-1 acts
as immunosuppressant reducing the ability of the infected
host to mount an adequate immune response to organisms
that require a Th2-dependent response.5,6
CASE REPORT
On March 14, 2014, a 35-year-old Peruvian man, body mass
index (BMI) = 24.9, was admitted to the University Division of
Infectious Diseases at Siena University Hospital (Siena, Italy)
because of acute onset of severe headache, mental confusion,
vomiting, and abdominal pain.
The patient had migrated to Italy from Peru 7 years before
and he had never traveled back to his country of origin. Since
2008, he was admitted four times to different Italian hospitals
with meningitis. In the first two instances, cerebrospinal fluid
(CSF) culture yielded Escherichia coli and Enterococcus
faecium, respectively, while two other episodes were diag-
nosed clinically since repeated attempts to perform lumbar
puncture failed. During the first episode of meningitis, because
of concomitant severe abdominal pain, he underwent an
explorative laparotomy that did not reveal any abnormal find-
ing. S. stercoralis larvae were found in stool microscopy dur-
ing the first three episodes of meningitis. He was treated
with different antihelmintic regimens, namely mebendazole
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500 mg qid for 10 days, thiabendazole 500 mg bid for 5 days,
albendazole 200 mg bid for 6 days and another course of
albendazole with unspecified dosage and duration.
Physical examination revealed fever (body temperature
38°C), neck stiffness, positive bilateral Lase`gue sign, and
red dermographism. Blood tests were normal except for
18,060 leukocytes/mL (80% neutrophils) and C-reactive protein
1.01 mg/dL (reference value < 0.5 mg/dL).
Chest x-ray, abdominal ultrasound, and brain computed
tomography (CT) scan did not reveal any alteration. Several
attempt to lumbar puncture failed, because of difficulties
related to anatomical conformation.
Parasitological stool examinations showed S. stercoralis
larvae both in microscopic examination of three stool samples
collected on alternate days and in Koga-agar plate culture. In
brief, three stool samples were collected on alternate days in
the concentration system of intestinal parasites, Paraprep
S Gold Plus Kit (DiaMondial, Se´es, France), and processed
according to the manufacturer’s instructions. Microscopic
examination of the sediment revealed the presence of numerous
S. stercoralis rhabditoid larvae in all the three samples. A mod-
ified method for S. stercoralis agar plate culture was performed
as reported: a stool sample was cultured on multiple Mueller
Hinton 2 agar plates (Biomerieux, Durham, NC); plates were
sealed, incubated for 2–7 days at 22°C, protected from light.
Plates were daily checked for tracks left by larvae and suspi-
cious areas observed under a stereomicroscope (dissection
microscope). After the first 18 hours incubation, S. stercoralis
rhabditoid larvae were observed on the edge of the inoculum.
Although serology (SeroELISA Strongyloides IgG; IVD
Research Carlsbad, CA)7 was negative.
HTLV antibodies were tested by a commercial chemilumi-
nescent microparticle immunoassay (Architect rHTLV-I/II
assay; Abbott, Wiesbaden-Delkenheim, Germany), according
to manufacturer’s instructions, and resulted strongly positive
(index 128.20, cutoff value for positivity = 1). No other cause
of acquired or congenital immunodeficiency was revealed.
HIV ELISA test was negative, serum immunoglobulins were
within normal range, and so were complement dosage and
lymphocytic subset count.
Strongyloides serology was performed again at the Center for
Tropical Diseases, Sacro CuoreHospital, Negrar, Verona, Italy,
with an in-house indirect immunofluorescence antibody test
(IFAT)8 (negative), and with a commercial ELISA (Bordier
ELISA; Bordier Affinity Products, Switzerland)9 that showed
a slight positivity (index 1.1, cutoff value for positivity = 1).
Blood cultures for bacteria and fungi performed on
admission were negative. The patient was also screened for
hepatitis B and C, Toxocara canis, Trypanosoma cruzi, echi-
nococcus, and cysticercus serologies, which were all negative.
On admission, blood cultures were performed and empiri-
cal, broad-spectrum antimicrobial treatment was started
(meropenem 2 g tid, vancomycin 1 g bid, and acyclovir
750 mg tid). Acyclovir was discontinued after 7 days as her-
petic encephalitis was deemed very unlikely, vancomycin was
stopped on 14th day, while meropenem was continued for a
total of 3 weeks.
Strongyloidiasis could not be treated as the drug of choice,
ivermectin, was not registered in Italy, and was requested from
the local pharmacy but not retrieved in time before discharge.
On the 21st day, the patient was discharged in excellent
clinical conditions. After discharge, patient was referred to
the Tuscany Reference Center for Tropical Diseases, Azienda
Ospedaliero-Universitaria Careggi, Florence (Italy), where a
small stock of ivermectin was available.
The case was discussed within the “World Health Organi-
zation Strongyloidiasis Information Sharing Platform” (http://
ezcollab.who.int/ntd/strongyloidiasis), which is an internet-
based system accessed by invitation only, intended to share
information and exchange opinions among the subcommunity
members on key issues of strongyloidiasis, to decide the man-
agement strategy. Three different strategies were suggested
by three different experts (Table 1).
After discussion, the patient was treated with a first cycle of
200 mg/kg/dose ivermectin once daily on day 1, 2, 15, and 16.
The first dose was administered under medical surveillance,
while the rest of the doses were delivered to the patient who
completed the regimen at home. Follow-up with full blood
cell count, Strongyloides serology, direct parasitological
examination of stool, stool culture, and polymerase chain
reaction (PCR) for Strongyloides were scheduled but, unfor-
tunately, the patient did not present to any follow-up appoint-
ment despite several telephone reminders and attempts to
reschedule the follow-up visits. After 6 months of ivermectin
treatment, the patient did not complain of any symptom at
telephone follow-up. A parasitological screening of all family
members (the wife and two children) was also repeatedly
suggested, without any success so far.
DISCUSSION
The case presented highlights the possibility of recurrent
meningitis due to intestinal bacteria in HTLV-1-infected
patients with strongyloidiasis refractory to treatment.
Even though a test to distinguish among HLTV-1 and
HTLV-2, such as a Western blot, was not performed, the
patient was most likely infected with HTLV-1 given the epi-
demiological distribution of the virus in the patient’s country
of origin10 and because, unlike HTLV-2, HTLV-1 only
has been associated with complicated strongyloidiasis.6,11
Table 1
Management strategies for the patient described in the case report proposed by some of the members of the “World Health Organization
Strongyloidiasis Information Sharing Platform” (http://ezcollab.who.int/ntd/strongyloidiasis)
Expert number Proposed treatment strategy Proposed follow-up strategy
Expert 1 Albendazole 400 mg bid plus ivermectin 200 mg/kg/dose once daily
for two consecutive days a week for at least 1 month
Stool culture, PCR, serology
Expert 2 Ivermectin 200 mg/kg/dose once daily on day 1, 2, 15 and 16 Stool culture only
Expert 3 Ivermectin 200 mg/kg/dose once daily for 2–5 days
(depending on the larval burden), repeat at days 14 and 15
Stool culture, PCR, serology
Secondary prophylaxis may be required
for some patients who fail therapy
PCR = polymerase chain reaction.
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Strongyloides hyperinfection is strongly associated with
HTLV-1 infection in Peru.12
Meningitis in association with strongyloidiasis is usually
due to intestinal pathogens and diagnosed in severely immu-
nocompromised patients who develop disseminated strongy-
loidiasis,4 a condition with a fatality rate of about 70%.3
Recurrent episodes of bacterial meningitis in patients with
strongyloidiasis are reported in subjects presenting predispos-
ing factors, such as organ transplant,13 corticosteroid use,14
diabetes,14 and HTLV-1 infection.15
The association of strongyloidiasis and meningitis is not
infrequent in some endemic areas where S. stercoralis and
HTLV-1 are co-endemic, such as subtropical areas of Japan.
In a recent case series, 33 meningitis episodes in 21 patients
with strongyloidiasis in a 10-year period were described, with
five patients presenting recurrent episodes. Out of 21 patients,
16 were HTLV-1 positive, and all 5 patients with recurrent
episodes were also HTLV-1 positive.15 In 19 out of 33 epi-
sodes described in this series, blood and/or CSF culture
yielded intestinal bacteria (with Klebsiella pneumoniae,
Streptococcus bovis, and Escherichia coli being the most fre-
quently isolated), while 14 out of 33 cases were culture negative
suggesting that the parasite itself may invade the meninges
without any concurrent bacteria, and that S. stercoralis alone
may induce the intense inflammatory changes that mimic the
CSF findings of bacterial meningitis, as already hypothesized
by Kishaba and others.16
HTLV-1 interferes with Th2 cell responses to S. stercoralis,
including eosinophils activation and production of interleukins
and IgE.17 Moreover, a poor response to antihelmintic treat-
ment (ivermectin, albendazole, and thiabendazole) of
S. stercoralis has been observed inHTLV-1-infected individuals.6
In uncomplicated strongyloidiasis, ivermectin is the drug of
choice because it is more effective than albendazole18 and
better tolerated than thiabendazole,19 although the optimal
dosage and schedule of ivermectin has yet to be determined.
Management strategies for severe case of strongyloidiasis,
such as the one reported in this article, are not yet standard-
ized. A recent systematic review of literature based on case
reports and short case series of severe strongyloidiasis outline
a “Babylon of different treatment schemes.”3 Even the differ-
ent suggestions for our case provided by the consulted experts
through the web-based platform confirm the lack of a stan-
dardized treatment approach to this condition. However, all
consulted experts agreed on including repeated doses of iver-
mectin in the treatment strategy and on the need for a strict
follow-up to assess cure. As far as follow-up is concerned, a
combination of all available laboratory techniques including
stool culture, serology, and PCR is probably the best strategy
to achieve the highest sensitivity to detect a treatment failure,
even if the interpretation of serology may be critical and
evidence for the usefulness of PCR in this context is lacking.20
Our case underlines several crucial points concerning the
management of poorly known neglected infectious diseases
such as strongyloidiasis and HTLV-1 in a low-endemic area
in the “global health era.”
The migrant patient was repeatedly admitted to different
Italian hospitals for meningitis and strongyloidiasis, but the
two conditions had never been causally linked. He had never
been tested for HTLV-1 nor treated with ivermectin, the drug
of choice for strongyloidiasis. He underwent an invasive,
explorative laparotomy because of severe abdominal pain
most likely due to strongyloidiasis, which could have been
avoided if the parasitic infection had been properly suspected
and managed.
Our case also confirms the possibility of false-negative
Strongyloides serology in immunocompromised patients21–23
with severe forms of strongyloidiasis demonstrating the irre-
placeable and complementary role of appropriate parasitolog-
ical investigation (particularly stool culture).
Our experience also underscores the difficulties in obtaining
ivermectin that is not registered in some countries and that
may be urgently needed to treat a severe infection.
Finally, we wish to underline the usefulness of the “World
Health Organization Strongyloidiasis Information Sharing
Platform,” the internet-based system that allowed to easily
share opinions with experts on the management strategy.
On the basis of our case report and on the literature avail-
able, we suggest conclusive few, key take-home messages, as
summarized in Table 2.
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Table 2
Take-home message learned from this case
1) Clinicians working in non-endemic areas should be aware of neglected infectious diseases such as strongyloidiasis and HTLV-1, which, if
associated, may determine a fatal outcome
2) Patients with meningitis due to intestinal bacteria should undergo serological and parasitological test for strongyloidiasis
3) Patients with meningitis and strongyloidiasis, as well as those with strongyloidiasis who fail to respond to antiparasitic treatment, should be
tested for HTLV-1
4) In immunocompromised patients with strongyloidiasis, serology for Strongyloides may be falsely negative, and fecal-based tests, including
culture for Strongyloides, are mandatory
5) Ivermectin should be made universally available for the treatment of strongyloidiasis
6) In HTLV-1 infected patients, efficacy of standard antihelmintic regimens is reduced, therefore strongyloidiasis must be treated aggressively
HTLV-1 = human T cell lymphotropic virus type 1.
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